North Thames CA125 study in advanced ovarian cancer

North Thames CA125 study in advanced ovarian cancer: a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN75843298

Enrollment

237

Registered

2001-07-01

Start date

1989-12-05

Completion date

Unknown

Last updated

2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer Cancer Ovarian cancer

Interventions

Patients are randomised to one of two treatment schedules: 1. Schedule A: Carboplatin or cisplatin repeated every four weeks for a total of five courses. CA125 measurement to be carried out prior to

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed diagnosis of invasive epithelial ovarian carcinoma 2. International Federation of Gynaecology and Obstetrics (FIGO) stage Ic, II, III or IV 3. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 4. Aged 18 - 75 years 5. Adequate renal, hepatic and bone marrow function 6. Life expectancy of at least 3 months 7. No history of previous malignancy, except basal cell carcinoma of the skin or in situ carcinoma of the cervix 8. No medical contra-indications to protocol treatments

Exclusion criteria

Exclusion criteria: Does not comply with above inclusion criteria.

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026